China NMPA Drug Inspection - Shijiazhuang Yiling Pharmaceutical Co., Ltd. - Lianhua Qingwen Capsules

The Gansu Provincial Drug Administration, under China's National Medical Products Administration (NMPA), carried out comprehensive quality sampling inspections on drugs designated for COVID-19 prevention and control. These inspections were conducted throughout February 2020 across 14 cities/prefectures and the Lanzhou New Area in Gansu Province, with results officially announced on March 20, 2020. A total of 502 batches of various pharmaceutical products were sampled from numerous manufacturers and distribution points, including traditional Chinese medicines like Lianhua Qingwen Capsules and Shuanghuanglian Oral Liquid, as well as Western medications such as Prednisolone Acetate Tablets and Ribavirin Injection. The regulatory framework for these assessments primarily adhered to the "Chinese Pharmacopoeia 2015 Edition, Parts I and II," supplemented by specific national drug standards. Notably, all 502 sampled batches demonstrated full compliance with the established quality standards. Consequently, no violations or quality issues were identified during this inspection initiative, and therefore, no corrective or required actions were mandated from the inspected entities.